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S212 Poster Session IMethods: Monocyte-derived dendritic cells (mo-DC) were used
to present antigens from 5 viruses to T cells of normal donors.
CMV, EBV and human adenovirus (HadV) antigens were pre-
sented by transfection of mo-DC with recombinant adenovirus
vectors containing CMV pp65 and EBV EBNA1, LMP1 and
LMP2a genes. mo-DC were infected with the live attenuated
VZV OKA strain and incubated with overlapping peptide mixes
covering the BKV proteins LTA, STA, VP1, VP2 and VP3. After
two weekly mo-DC stimulations the cell product was cultured in
IL-2 for 21 days.
Results: The final multi-virus cell products from 9 cultures in-
creased in cell number from baseline (mean increase was 9-fold),
were predominantly CD3 positive (mean 92% range 85 to 97%).
There was significant variation between individuals in CD4:8 ratio.
Mean CD8 was 39%, range 3 to 71%, and CD4 was 50% range 26
to 92%. The majority of cells expressed CD45RO1 (mean 87%).
Amean of 27% of cells retained expression of CD62L.The total per-
centage of antigen specific T cells as measured by cytokine produc-
tion ranged from 3 to 52% (mean 15%). This was composed of both
CD4 (mean 13%) and CD8 cells (mean 20%). The mean percent of
cells responding to each antigen was as follows: CMV 6.3%, EBV
3.7%, BKV 2.1%, VZV 13.9% and Hadv 1%. Fold increase in
MHC multimer positive cells compared to baseline was as follows:
CMVpp65 HLA-A2 NLV 1742-fold, CMVpp65 HLA-B7 TPR
1689-fold, EBV LMP2a HLA-A2 CLG 124-fold, EBV LMP2a
HLA-A2 FLY 180-fold. Cells were analysed for production of IL-
2, interferon-gamma and TNF. Single cells producing one, two
and all three cytokines were observed in response to stimulation
with all antigens.
Discussion: This method allows for the rapid production of T cells
specific for 5 viruses for use in adoptive immunotherapy postHSCT.
It is not HLA-dependent and is rapid thus potentially enhancing the
protection available to immunocompromised transplant recipients.
The use of antigen and reagent sources that are consistent
with Good Manufacturing Practice will allow for rapid clinical
translation.159
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Hematopoietic Stem Cell Transplantation is the treatment of
choice for many common malignancies. However, recipients are
susceptible to viral infections after transplant. Antiviral drugs can
be effective, but are toxic and can become drug-resistant. Another
option is the administration of virus-specific donor-derived cytotoxic
T lymphocytes (CTL). Using a chimeric adenovirus expressing the
immunodominant CMV antigen pp65 (Ad5f35pp65) to modify anti-
gen-presenting cells, we generated CTL specific for EBV,
CMVpp65 and Adenovirus (Multivirus-specific CTL) from healthy
donors. We have infused 26 patients with multivirus-specific CTL
and have shown protection against all 3 viruses in vivo without sig-
nificant toxicity. However, while all patients have been protected
against EBV and Adenovirus,. 10%of patients developedCMV re-
activation after CTL infusion, suggesting that targeting a single
CMV antigen may not be entirely protective. After solid organ
transplantation, IE-1-specific T cells were shown to be themost pro-
tective against CMV infection and after CMV vaccine, recipients
have a stronger and more robust IE-1 response when compared to
pp65. Therefore we sought to develop a GMP-compliant strategy
to generate CTL targeting twoCMV antigens (pp65 and IE-1) while
not losing the breadth of specificity to EBV and adenovirus. CTL
were generated by transducing monocytes (first stimulation) and
then EBV-LCL with an Ad5f35-IE-1-I-pp65 vector at subsequent
stimulations. Resultant T cells recognized CMV pp65 (mean:330;
median:273; range:47-995) and IE-1 (mean:154; median:154;
range:11-505), Adenovirus hexon (mean:189; median:153;range:30-465) and penton (mean:109; median:37 range:1-353), and
EBV-LCL(mean:79; median: 55 range:9-301) as measured by
IFN-g ELISPOT and pentamer analysis. CTL were also able to
lyse EBV, CMV, and adenovirus targets in cytotoxicity assays as
well as HLA-matched CMV AD169-infected allogeneic fibroblasts.
Importantly, the new multivirus-CTL recognize at least two anti-
gens per virus, in addition to recognizing a breadth of epitopes
within each antigen. In conclusion, we have developed a strategy
to expand multivirus CTL targeting at least 2 antigens from EBV,
CMV, and adenovirus thus increasing the breadth of the antiviral re-
sponse and have begun the process of translating this to the clinic to
improve immunity to CMV after transplantation.160
CYTOMEGALOVIRUS (CMV) PP65 SPECIFIC T CELLS EXPANDED FROM
MOBILISED PERIPHERAL BLOOD STEM CELL (PBSC) COLLECTIONS
FOR PROPHYLACTIC ADOPTIVE IMMUNOTHERAPY
Clancy, L., Blyth, E., Simms, R., Gottlieb, D. Westmead Millennium
Institute, Sydney, NSW, Australia
We have conducted two trials of donor derived CMV specific T
cells given prophylactically to HSCT recipients. Our results suggest
this controls CMV reactivation without the need for antiviral ther-
apy. The cells in these trials were derived from blood collected prior
to receivingG-CSF for stem cell mobilisation. Patients with overseas
donors have been ineligible for this therapy due to the logistical com-
plexities of obtaining a separate blood donation. This could be re-
solved if CMV specific T cells could be expanded from HSC
collections. The aims of this study were to generate CMV specific
T cells from G-CSF mobilised PBSC harvests, to assess the pheno-
type and function of these cells, and to conduct a phase I study of
their safety as adoptive immunotherapy.
PBMCwere isolated from up to 1.5% (0.8-4ml) of eight mobilised
PBSC collections. Monocyte derived dendritic cells were transfected
with a vector encoding CMVpp65 and co-cultured with PBMC to
stimulate expansion of T cells. Cultures were re-stimulated after 7
days and continued for 14 days with the addition of IL-2. At the
end of culture, cell number increased by 9 to 29 fold (mean 19)
and consisted primarily of T cells (mean 96.8%). T cells were of
memory phenotype with variable expression of CD62L (mean
13.4%, 2-29.8%). 7 of 8 cultures contained more CD8 (mean
76%, 45-93.8%) than CD4 T cells (19.4%, 4.9-53.7%). We ob-
served up to a 2061 fold increase in cells recognising a HLA-A2 re-
stricted CMV epitope. Specificity towards this epitope accounted for
16.6%, 49% and 75% of CD8 T cells in three donors. Five cultures
assessed by 51Cr release assay exhibited negligible alloreactivity
against allogeneic HLA matched target cells (0-1.7% lysis at an ef-
fector to target E:T ratio of 20:1) but strong killing of pp65 pulsed
targets (68.4-97.5% lysis at E:T 20:1). Five patients have been re-
cruited for a Phase I trial of prophylactic CMV specific T cell adop-
tive transfer using cells expanded from haemopoietic stem cell
harvests. Three have received infusions of 2x107 T cells per m2
with no adverse reactions. Patient follow up will monitor CMV reac-
tivation and immune reconstitution. In summary, generation of
CMV specific T cells starting from a mobilised stem cell product ap-
pears feasible and safe. Use of the stem cell product is convenient and
brings the generation of virus specific T cells within an established
regulatory framework that will facilitate more disseminated use of
adoptive immunotherapy.161
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Reactivation of cytomegalovirus (CMV) is a major barrier to the
success of organ and allogeneic stem cell transplantation (alloSCT).
Poster Session I S213Current management strategies are suboptimal and associated with
significant adverse effects. Patients undergoing alloSCT are pro-
foundly immunocompromised and do not respond to vaccination
with CMV antigens. Immunotherapy (IT) with CMV specific do-
nor-derived cytotoxic T lymphocytes (CTL) is effective after al-
loSCT, but is expensive, labor intensive, and difficult to replicate.
Non-toxic strategies are needed to improve outcomes. In earlier
studies, we showed that ex vivo expanded activated T cells (ATC)
armed with anti-CD3 anti-Her2/neu bispecific antibody (Her2Bi)
exhibit high levels of specific cytotoxicity directed at breast cancer
cell lines. Using this strategy, we tested ATC armed with anti-
CD3 (OKT3)  anti-CMV (Cytogam) bispecific antibodies
(CMVBi) to target and lyse CMV-infected fibroblasts. Normal do-
nor ATC were generated and armed with CMVBi. Specific cytotox-
icity was tested by 51Cr release using CMV-infected or uninfected
human fibroblasts. CMVBi alone, CMVBi-armed ATC (aATC),
and ATC alone were tested for their ability to kill. ATC were armed
with 0.001 to 500 ng of CMVBi/106ATC at effector:target (E:T)
from 3.125:1 to 25:1. IFNgEliSpot was used to assess IFNg secreting
cells in ATC and aATC after exposure to CMV-infected and unin-
fected fibroblasts. ATC armed with CMVBi as little as 0.001 ng/
106 ATC was significantly more cytotoxic than unarmed ATC.
There was higher cytotoxicity mediated by aATC as the multiplicity
of infection (MOI) increased in target cells. At all E:T, CMVBi arm-
ing at a dose of 50 ng/106 ATC exhibited dramatically higher lysis of
CMV-infected targets (MOI 1) than that exhibited by ATC alone.
Cytotoxicity mediated by unarmed and armed ATCwas background
in uninfected targets. Immunofluorescent studies showed that aATC
aggregated around GFP fluorescence-marked CMV-infected fibro-
blasts. Cytokine secretion analyzed by IFNg EliSpot confirmed im-
mune responses. The lack of MHC restriction in the mediation of
cytotoxicity, polyclonal targeting of multiple CMV antigens and
the simplicity of expanding donor T cells makes it easy to adapt
this effective strategy against CMV infection post alloSCT.162
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Adoptive transfer of virus-specific T cells can effectively restore
antiviral immunity after stem cell transplantation. However, proto-
cols for eliciting virus-specific T cells from existing memory T cells
of CMV-seropositive adult (CMVpos) donors have been ineffective
when applied to na€ıve cord blood (CB) transplant (CBT) recipients
due to absence of antigen-specific memory cells in these grafts.
We previously demonstrated that CMVpp65-specific T cells could
be generated from CB using a modified protocol and that 15/15
CB T cell lines recognized atypical epitopes of pp65. To test if na€ıve
T cells from CMV-seronegative donors (CMVnegs) also recognize
atypical epitopes, we again optimized our previous method.
CD45RA1 na€ıve T cells were selected from peripheral blood and
stimulated with pp65-pepmix-pulsed DC with IL7, IL12, and
IL15. For subsequent stimulations T cells were stimulated with
pp65-pepmix-pulsed EBV-LCL and IL15 or IL2. CMVpp65-spe-
cific T cells (CMV-CTL) expanded from 8 of 11 CMVnegs and
were primarily CD81 T cells (mean 71%). These T cells secreted
markedly more IFN-g in response to pp65 peptides (mean 224;
range: 38-611 SFC/1x105 cells) than to irrelevant peptides (mean
12;Range 3-37) as measured in Elispot assays. These T cells lysed
pp65-pulsed target cells (mean:48;Range:15-70%) but not negative
controls (mean 22;Range 4-40%) in cytotoxicity assays. As with
CB, CMVneg CMV-CTL were derived from na€ıve T cells and rec-
ognized only atypical pp65 epitopes. These findings raised the con-
cern that the viral epitopes presented by endothelial cells infectedwith CMV in patients might not present the atypical peptides recog-
nized by our CMV-CTL. We hypothesized that the epitopes pre-
sented to T cells by endothelial cells or other APCs after CMV
infection are different to those presented in our in vitro system.
We tested if different epitopes would dominate the na€ıve T cell re-
sponse to CMV AD169-infected fibroblasts and CMV VR1814-in-
fected DC. The responding na€ıve T cells were again specific for
atypical epitopes showing that these epitopes were indeed presented
by cells naturally infected with CMV. This reassured us that despite
their unusual repertoire, T cells derived from CB or CMVnegs
should control CMV infections.We are now evaluating their clinical
efficacy in recipients of CBT and soon Hematopoietic Stem Cell
Transplantation. These studies should determine if na€ıve T cells
primed in vitro are able to persist and establish memory in vivo.163
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First generation chimeric antigen receptors (CAR) usually combine
the antigenbindingdomainof amonoclonal antibodywith the z signal-
ing domain of theT cell receptor/CD3 complex.When expressed inT
cells, thoseCARprovide potent antigen-specific, nonMHC-restricted
effector function against tumor cells in vitro, but clinical trials have
shown limited expansion and persistence of these lymphocytes in
vivo. This limitation is likely attributable to the failure of these CAR
to fully activate T cells following target antigen engagement on tumor
cells, since tumors lack expression of costimulatorymolecules required
for sustainedT cell activation. Incorporation of costimulatory endodo-
mainswithin theCAR, such asCD28, increases proliferation and activ-
ity of themodifiedT cells in vitro andmay enhance their benefit in vivo
but, as yet, the relevanceand valueof thesemodifications inhumansub-
jects remains speculative.
We now present results from a phase I trial of T cells redirected to
CD19 given to patients with refractory/relapsed B-cell malignancies.
Patients were simultaneously infused with 2 autologous T cell prod-
ucts expressing CAR with identical CD19-specific exodomains. In
one product, the endodomain contained only the z sequence
(CAR.19z) while, in the second product, we added a costimulatory
CD28 domain (CAR.19-28z). We could thus directly measure and
compare the expansion, persistence and effectiveness of each cell
population in every patient. Six subjects have been treated at 3 cell
dose levels (Table). Persistence of CAR1 T cells was assessed in
blood by Q-PCR assays specific for each population.
Table 1. Characteristics of the infused CD19-redirected




(20:1 E:T ratio)CAR.19z T cells 44 ± 23 49 ± 22 6 ± 5 50 ± 24 53 ± 10CAR.18-28z T cells 47 ± 26 48 ± 22 6 ± 6 47 ± 66 65 ± 19All numbers are shown as mean percentage6 standard deviation. T cell
products were generated by activation of autologous peripheral blood
mononuclear cells with immobilized OKT3, gene modification with ret-
roviral vectors encoding either CAR.19z or CAR.19-28z and ex vivo ex-
pansion for a median of 14 days (range 6-18) in the presence of IL-2.
Three dose levels have been administered: 2107, 1108 and 2108
cells of each product/m2.
All infusions were well tolerated. CAR.19-28z cells were detected at
a low level after infusion, but progressively increased 7- to 63-fold,
peaking at 1-2 wk, before declining to background levels over the
